RNAZ Stock Overview A biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
TransCode Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for TransCode Therapeutics Historical stock prices Current Share Price US$3.53 52 Week High US$236.94 52 Week Low US$3.21 Beta 0.55 1 Month Change -60.92% 3 Month Change -81.85% 1 Year Change -98.17% 3 Year Change -99.99% 5 Year Change n/a Change since IPO -100.00%
Recent News & Updates
Transcode Therapeutics, Inc. Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1TTX-MC138 Clinical Trial Dec 18
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split to Meet the Minimum Bid Price Requirement Dec 03 TransCode Therapeutics, Inc. announced that it expects to receive $8 million in funding Nov 27
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split to Regain Compliance with Nasdaq Bid Price Requirement Nov 26
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance Nov 06
Transcode Therapeutics, Inc. Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1Ttx-Mc138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data Oct 25 See more updates
Transcode Therapeutics, Inc. Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1TTX-MC138 Clinical Trial Dec 18
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split to Meet the Minimum Bid Price Requirement Dec 03 TransCode Therapeutics, Inc. announced that it expects to receive $8 million in funding Nov 27
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split to Regain Compliance with Nasdaq Bid Price Requirement Nov 26
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance Nov 06
Transcode Therapeutics, Inc. Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1Ttx-Mc138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data Oct 25
Transcode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, A MicroRNA-Targeted Technology Oct 10
TransCode Therapeutics, Inc. Receives Non-Compliance Letter from Staff of Nasdaq Sep 28
TransCode Therapeutics, Inc. Announces First Patients Treated in Phase 1 Clinical Trial with First-In-Class Lead Therapeutic Candidate Sep 17
TransCode Therapeutics Receives Deficiency Letters from the Listing Qualifications Department (The “Staff”) of the Nasdaq Aug 17
TransCode Therapeutics, Inc. Announces Phase 1 Clinical Trial Initiation Aug 15 TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $3 million. Jul 25
TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering. Jul 23
TransCode Therapeutics, Inc. Reports Positive Data from First-In-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138 May 30
TransCode Therapeutics Intends to File a Request for a Hearing on or before May 14, 2024, in Response to Non-Compliance with the Nasdaq Listing Rule 5550(a)(2) May 11
TransCode Therapeutics, Inc., Annual General Meeting, Jun 13, 2024 May 01
TransCode Therapeutics, Inc. Announces Fda Clearance to Initiate Phase 1/2 Clinical Trial Withttx-Mc138 in Patients with Advanced Solid Tumors Apr 16
TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer Mar 28
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic Feb 20 TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.194863 million. Jan 24
TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.25 million. Jan 23
TransCode Therapeutics, Inc. Announces CEO Changes Jan 14 TransCode Therapeutics, Inc. Announces CEO Changes TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering. Jan 11
TransCode Therapeutics, Inc. Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with Its Lead Candidate, TTX-MC138 Dec 13
TransCode Therapeutics, Inc. to Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium Dec 06 TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $1.21 million. Dec 05
TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.21 million. Dec 02
TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.21 million. Dec 01
TransCode Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Required for Continued Listing on The Nasdaq Capital Market Nov 10 Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on the Nasdaq Stock Market Subject to Conditions
Transcode Therapeutics, Inc. Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Leading Therapeutic Candidate, Tx-Mc138 Oct 26
TransCode Therapeutics, Inc. Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate,TTX-MC138 Sep 26
TransCode Therapeutics, Inc. Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial Aug 24
TransCode Therapeutics Provides Non Compliance Update Aug 05
TransCode Therapeutics Receives Delisting Determination Letter from Nasdaq Advising Not to Accept its Compliance Plan, and Denies its Request for an Extension Jul 31
TransCode Therapeutics, Inc. Announces Publication of New Data Supporting Use of TTX-MC138 for Treatment of Metastatic Breast Cancer Jun 23
New major risk - Shareholder dilution Jun 10
TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Lead Candidate, Tx-MC138, in Glioblastoma Jun 09
TransCode Therapeutics Announces 1-For-20 Reverse Stock Split to Satisfy the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market May 23
TransCode Therapeutics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement May 19
TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma Feb 02
Transcode Therapeutics, Inc. Announces FDA Authorization to Proceed with First-In-Human Clinical Trial Dec 30
Transcode Therapeutics Announces Eind Submission to Us Fda for Planned First-In-Human Clinical Trial in Patients with Advanced Solid Tumors Dec 01
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma Nov 10
TransCode Therapeutics, Inc. Reports Positive Preclinical Results with Its Lead Candidate, TTX-MC138 Oct 27
TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology Oct 14
TransCode Therapeutics, Inc. Appoints Frank J. Slack to its Advisory Board Sep 09
TransCode Therapeutics reports Q2 results Aug 15
TransCode files U.S. patent application for radiotherapy based cancer treatment Jul 11
Co-Founder recently bought US$55k worth of stock Jun 02
TransCode Therapeutics, Inc. Acquires Option for Radiotheranostic Technology May 20
TransCode Therapeutics, Inc., Annual General Meeting, Jun 22, 2022 May 03
We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely Apr 01
Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation Dec 15
TransCode Therapeutics, Inc. Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer Sep 24 Shareholder Returns RNAZ US Biotechs US Market 7D -9.3% -2.3% -2.6% 1Y -98.2% -6.3% 24.5%
See full shareholder returns
Return vs Industry: RNAZ underperformed the US Biotechs industry which returned -6.3% over the past year.
Return vs Market: RNAZ underperformed the US Market which returned 24.5% over the past year.
Price Volatility Is RNAZ's price volatile compared to industry and market? RNAZ volatility RNAZ Average Weekly Movement 22.4% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.7% 10% least volatile stocks in US Market 3.1%
Stable Share Price: RNAZ's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RNAZ's weekly volatility has decreased from 27% to 22% over the past year, but is still higher than 75% of US stocks.
About the Company TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company’s lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells.
Show more TransCode Therapeutics, Inc. Fundamentals Summary How do TransCode Therapeutics's earnings and revenue compare to its market cap? RNAZ fundamental statistics Market cap US$1.76m Earnings (TTM ) -US$14.93m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) RNAZ income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$14.93m Earnings -US$14.93m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 00:34 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources TransCode Therapeutics, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Emily Bodnar H.C. Wainwright & Co.
Show 0 more analysts 
